Crescent Biopharma Advances CR-001 Cancer Trial and Combination Studies
Crescent Biopharma said more than 125 patients have been dosed in the global Phase 1/2 ASCEND trial of CR-001, a PD-1 x VEGF bispecific antibody. The company is enrolling patients in chemotherapy combination cohorts and additional antibody-drug conjugate combination studies, with initial monotherapy data expected in the first quarter of 2027. Crescent expects initial data from hundreds of patients in mid-2027 and may begin Phase 3 studies in early 2028.
Crescent Biopharma’s global Phase 1/2 ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, has completed dose finding, with more than 125 patients treated in the U.S., Europe, and South Korea. Initial monotherapy results are expected in Q1 2027, including response data from a first-line non-small cell lung cancer cohort.
The trial is also enrolling chemotherapy combination cohorts across several solid tumors, such as first-line NSCLC, colorectal, biliary tract, gastric, and endometrial cancers, in treatment-naive and previously treated patients. Data from hundreds of patients are anticipated in mid-2027, with a possible first Phase 3 study starting in early 2028.
If CR-001 and related combinations succeed, patients with hard-to-treat solid tumors could gain additional treatment options, potentially reshaping care pathways and trial participation. Clinicians and researchers may see more combination strategies, while health systems could face new cost and access questions. Early-stage results may also influence investment and partnership activity in oncology. However, benefits remain uncertain until larger trials confirm safety and efficacy, so patients and providers should view timelines as provisional.